Daymark Wealth Partners LLC Trims Holdings in Solventum Co. (NYSE:SOLV)

Daymark Wealth Partners LLC lowered its holdings in shares of Solventum Co. (NYSE:SOLV) by 50.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,570 shares of the company’s stock after selling 3,628 shares during the period. Daymark Wealth Partners LLC’s holdings in Solventum were worth $236,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Modus Advisors LLC acquired a new stake in shares of Solventum during the fourth quarter worth about $25,000. Copeland Capital Management LLC purchased a new stake in Solventum during the 3rd quarter valued at approximately $26,000. Mather Group LLC. acquired a new stake in Solventum during the 3rd quarter worth approximately $27,000. Twin Lakes Capital Management LLC purchased a new position in shares of Solventum in the 2nd quarter valued at approximately $29,000. Finally, True Wealth Design LLC increased its holdings in shares of Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after purchasing an additional 471 shares during the period.

Analysts Set New Price Targets

Several brokerages recently weighed in on SOLV. Piper Sandler increased their price target on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Mizuho began coverage on shares of Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 target price for the company. Morgan Stanley boosted their price target on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Finally, Stifel Nicolaus started coverage on shares of Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price objective for the company. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Solventum presently has a consensus rating of “Hold” and a consensus target price of $68.29.

Solventum Stock Performance

SOLV stock opened at $74.93 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The company’s 50-day moving average price is $69.41 and its 200 day moving average price is $66.13. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $96.05.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, November 7th. The company reported $1.15 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.23). The firm had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.05 billion. On average, equities analysts expect that Solventum Co. will post 6.58 EPS for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.